jak-in-10

JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.

Ivarmacitinib (SHR0302) sulfate, a potent and orally active inhibitor of all JAK family members, exhibits particular selectivity towards JAK1. Its selectivity is >10-fold greater for JAK1 compared to JAK2, 77-fold more than JAK3, and 420-fold more than Tyk2. Ivarmacitinib effectively inhibits JAK1-STAT3 phosphorylation, thereby inducing apoptosis in hepatic stellate cells. Additionally, it demonstrates notable anti-proliferative and anti-inflammatory properties [1] [2].

BVB808 (NVP_BVB808) is a selective inhibitor of JAK2, exhibiting approximately 10 times greater selectivity for JAK2 compared to other members of the JAK family (such as JAK1, JAK3, or TYK2) in vitro. By inhibiting the activation of JAK2, BVB808 reduces the phosphorylation of STAT5, thereby blocking the cell proliferation and survival signaling pathways that depend on JAK2. This compound is utilized in cancer research.